Andrew Puca, PhD presents techniques for optimizing preclinical diabetes research in spontaneously diabetic NHPs, with a focus on stress-free assessments of glucose measurement and response using continuous glucose monitoring and the banana tolerance test.

The key to fighting type 2 diabetes is to develop and utilize novel agents that control multiple disease aspects, rather than individual diabetes components such as hyperglycemia, hypertension, or dyslipidemia alone. To assess new agents, and facilitate faster progression to the clinic, more clinically relevant preclinical models are needed, that mimic full human disease progression.

Non-human primates (NHP) which spontaneously develop diabetes, show all of the characteristics and comorbidities of human type 2 diabetes at different stages of the progressive disease. They provide the most predictive animal model system for preclinical diabetes research, and are combined with novel techniques to reduce invasiveness and stress, leading to improved clinical outcomes and study data.

In this webinar hosted by CrownBio, Dr. Andrew Puca explores unique techniques for optimizing preclinical diabetes research in spontaneously diabetic NHPs. He focuses on stress free assessments of glucose measurement and response in NHPs using continuous glucose monitoring and the banana tolerance test.

Presenters

Senior Business Development Director
CrownBio

Production Partner

Crown Bioscience

Crown Bioscience brings clarity to drug discovery around the world by helping biopharmaceutical companies solve some of today's most pressing challenges in oncology, inflammation, cardiovascular, and metabolic disease. Our premier Translational Platforms help our clients accelerate their new drug development programs.

Additional Content From Crown Bioscience

Related Content